WallStreetZenWallStreetZen

NYSE: BMY
Bristol Myers Squibb Co Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Bristol Myers Squibb Co earnings were $5.4B for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest BMY earnings report on Mar 31, 2025 announced Q1 2025 earnings of $2.5B, up 3,311.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BMY reported annual earnings of -$8.9B, with -211.5% growth. The next BMY earnings date is Jul 31, 2025.

BMY past earnings growth

How has BMY's earnings growth performed historically?

Company
N/A
Industry
113.13%
Market
34%
BMY's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
BMY's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance

BMY earnings history

Current Revenue
$47.6B
Current Earnings
$5.4B
Current Profit Margin
11.4%
BMY's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

BMY Return on Equity

Current Company
31.9%
Current Industry
53.5%
Current Market
31.5%
BMY's Return on Equity (31.9%)... subscribe to Premium to read more.
High Return on Equity Performance

BMY undefined

Current Company
5.8%
Current Industry
10.1%
BMY is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when BMY announces earnings.

BMY undefined

Current Company
8.91%
Current Industry
17.1%
BMY's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BMY vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
BMY$14.17B$5.42B+33.17%$2.68
GSK$6.16B$4.15B-9.52%$2.03
SNY$11.90B$5.79B+13.35%$2.31
GILD$10.58B$5.97B+4.06%$4.77
PFE$14.27B$7.88B-13.01%$1.39
View Top General Drug Manufacturer Stocks

BMY earnings dates

Next earnings date
Jul 31, 2025

Bristol Myers Squibb Co Earnings Reports & History FAQ

What were Bristol Myers Squibb Co's earnings last quarter?

On BMY's earnings call on Invalid Date, Bristol Myers Squibb Co (NYSE: BMY) reported Q1 2025 earnings per share (EPS) of $1.21, up 120.54% year over year. Total BMY earnings for the quarter were $2.46 billion. In the same quarter last year, Bristol Myers Squibb Co's earnings per share (EPS) was -$5.89.

If you're new to stock investing, here's how to buy Bristol Myers Squibb Co stock.

When does Bristol Myers Squibb Co report earnings?

The next BMY earnings date is Invalid Date. Add BMY to your watchlist to be reminded of Bristol Myers Squibb Co's next earnings date.

Is Bristol Myers Squibb Co profitable or losing money?

As of the last Bristol Myers Squibb Co earnings report, Bristol Myers Squibb Co is currently profitable. Bristol Myers Squibb Co's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $5.42 billion, a 188.14% decrease year over year.

What was BMY's earnings growth in the past year?

As of Bristol Myers Squibb Co's earnings date in Invalid Date, Bristol Myers Squibb Co's earnings has grown year over year. BMY earnings in the past year totalled $5.42 billion.

What are Bristol Myers Squibb Co's earnings expectations?

The current EPS estimate for Bristol Myers Squibb Co's earnings report in Invalid Date is $1.71.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.